In June 2022 the Anti-Doping Agency of Kenya (ADAK) reported an anti-doping rule violation against the Athlete Mathew Kiplangat Saw after his sample tested positive for the prohibited substance Triamcinolone acetonide.
Following notification a provisional suspension was ordered. The Athlete filed a statement in his defence and the case was referred to the Kenya Sports Disputes Tribunal. There were delays in the proceedings attributed to the Athlete. He repeatedly failed to respond, nor attended the hearing of the Tribunal.
Prior the Athlete had admitted the violation and denied the intentional use of the substance. He explained with medical information that the prescribed substance was used in a hospital as treatment for his knee injury.
ADAK contended that the Athlete failed to demonstrate that the violation was not intentional, nor how the substance had entered his system. Also ADAK requested the Panel for an additional sanction because its investigation had established that the medical evidence produced by the Athlete were falsifications.
The Panel finds that the presence of a prohibited substance has been established in the Athlete's sample and accordingly that he committed an anti-doping rule violation.
The Panel determines that the Athlete failed to establish that the violation was not intentional, nor how the substance had entered his system. The Panel deems that the Athlete clearly acted intentionally in view of the falsified medical information.
Therefore the Panel decides on 29 June 2023 to impose a 4 year period of ineligibility on the Athlete, starting on 11 July 2022.
